SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

11/12/24 5:20:30 PM ET

Medical/Dental Instruments

Health Care

Get the next $IART alert in real time by email

SC 13G 1 r13g-integra20240930.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. __) Under the Securities Exchange Act of 1934 Integra Lifesciences Holdings Corp (Name of Issuer) Common Stock (Title of Class of Securities) 457985208 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) For IA & IAR [ ] Rule 13d-1(c) For LP if any [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out or a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 457985208 SCHEDULE 13G Page 2 of 5 1 Name of Reporting Person Fuller & Thaler Asset Management, Inc. IRS Identification No. of Above Person 94-3176968 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC USE ONLY 4 Citizenship or Place of Organization California 5 Sole Voting Power 3,906,320 NUMBER OF 6 Shared Voting Power SHARES BENEFICIALLY -0- OWNED BY EACH REPORTING 7 Sole Dispositive Power PERSON WITH 3,967,562 8 Shared Dispositive Power -0- 9 Aggregate Amount Beneficially Owned by each Reporting Person 3,967,562 10 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* [ ] 11 Percent of Class Represented by Amount in Row 9 5.11% 12 Type of Reporting Person* IA CUSIP No. 457985208 SCHEDULE 13G Page 3 of 5 Item 1(a). Name of Issuer. Integra Lifesciences Holdings Corp Item 1(b). Address of Issuer's Principal Executive Offices. 1100 Campus Road Princeton, NJ 08540 Item 2(a). Names of Persons Filing. Fuller & Thaler Asset Management, Inc. Item 2(b). Address of Principal Business Office or, if none, Residence. 411 Borel Avenue, Suite 300, San Mateo, CA 94402. Item 2(c). Citizenship. California corporation. Item 2(d). Title of Class of Securities. Common Stock Item 2(e). CUSIP Number. 457985208 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company act of 1940 (15 U.S.C. 80a-8). CUSIP No. 457985208 SCHEDULE 13G Page 4 of 5 (e) [X] An investment adviser in accordance with 240.13d- 1(b)(1)(ii)(E). (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F). (g) [ ] A parent holding company or control person in accordance with 240.13b-1(b)(1)(ii)(G). (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). (i) [ ] A church plan that is excluded form the definition of an investment company under section 3(c)(14) of the Investment Company act of 1940 (15 U.S.C. 80a-3). (j) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(J). Item 4. Ownership. Reference is made hereby to Items 5-9 and 11 of Page two (2) of this Schedule 13G, which Items are incorporated by reference herein. Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Fuller & Thaler Asset Management, Inc. is deemed to be the beneficial owner of the number of securities reflected in Items 5-9 and 11 of page two (2) of this Schedule 13G pursuant to separate arrangements whereby it acts as investment adviser to certain persons. Each person for whom Fuller & Thaler Asset Management, Inc. acts as investment adviser has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock. Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable. CUSIP No. 457985208 SCHEDULE 13G Page 5 of 5 Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certification. By signing below, Fuller & Thaler Asset Management, Inc. certifies that, to the best of its knowledge and belief, the securities referred to above on page two (2) of this Schedule 13G were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. DATED: November 11, 2024 Fuller & Thaler Asset Management, Inc. /s/ Hanna Zanoni ________________________ By: Hanna Zanoni its: Chief Compliance Officer

Get the next $IART alert in real time by email

Recent Analyst Ratings for

$IART

Date	Price Target	Rating	Analyst
3/31/2025		Hold → Buy	Argus
12/2/2024	$25.00 → $20.00	Underweight	Morgan Stanley
10/7/2024		Sell → Neutral	BTIG Research
7/30/2024	$22.00	Neutral → Sell	BTIG Research
7/30/2024	$30.00 → $23.00	Neutral → Sell	Citigroup
5/7/2024		Outperform → Perform	Oppenheimer
5/7/2024	$45.00 → $25.00	Overweight → Equal Weight	Wells Fargo
4/3/2024	$38.00	Sell → Neutral	Citigroup

More analyst ratings

SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

11/12/24 5:20:30 PM ET

$IART

Medical/Dental Instruments

Health Care

Get the next $IART alert in real time by email

Recent Analyst Ratings for

$IART

Date	Price Target	Rating	Analyst
3/31/2025		Hold → Buy	Argus
12/2/2024	$25.00 → $20.00	Underweight	Morgan Stanley
10/7/2024		Sell → Neutral	BTIG Research
7/30/2024	$22.00	Neutral → Sell	BTIG Research
7/30/2024	$30.00 → $23.00	Neutral → Sell	Citigroup
5/7/2024		Outperform → Perform	Oppenheimer
5/7/2024	$45.00 → $25.00	Overweight → Equal Weight	Wells Fargo
4/3/2024	$38.00	Sell → Neutral	Citigroup

More analyst ratings

SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$IART

SEC Form SC 13G filed by Integra LifeSciences Holdings Corporation

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$IART

$IART
Insider Trading

Director Essig Stuart disposed of $2,724,000 worth of shares (200,000 units at $13.62) and acquired $2,724,000 worth of shares (200,000 units at $13.62), decreasing direct ownership by 15% to 1,152,236 units (SEC Form 4)

EVP & Chief Financial Officer Knight Lea Daniels covered exercise/tax liability with 2,561 shares, decreasing direct ownership by 4% to 58,578 units (SEC Form 4)

SVP, Fin & Princ Acct Officer Mosebrook Jeffrey covered exercise/tax liability with 3,345 shares, decreasing direct ownership by 8% to 36,600 units (SEC Form 4)

$IART
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Integra LifeSciences Holdings Corporation

SEC Form S-8 filed by Integra LifeSciences Holdings Corporation

SEC Form 10-Q filed by Integra LifeSciences Holdings Corporation

$IART
Insider Purchases

Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

$IART
Press Releases

REPAY Appoints New Chief Financial Officer

Integra LifeSciences Reports Second Quarter 2025 Financial Results

Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025

$IART
Analyst Ratings

Integra upgraded by Argus

Morgan Stanley initiated coverage on Integra with a new price target

Integra upgraded by BTIG Research

$IART
Leadership Updates

REPAY Appoints New Chief Financial Officer

Jan De Witte joins GHO Capital as Operating Partner

Integra LifeSciences Announces Appointment of Mojdeh Poul as President and Chief Executive Officer

$IART
Financials

Integra LifeSciences Reports Second Quarter 2025 Financial Results

Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025

Integra LifeSciences Reports First Quarter 2025 Financial Results

$IART
Large Ownership Changes